Status:
COMPLETED
MargheRITA (Remote Intelligence for Therapeutic Adherence)
Lead Sponsor:
Advice Pharma Group srl
Conditions:
Multiple Myeloma
Solitary Plasmacytoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
It is essential to improve clinical efficiency and management of hematological and oncological patients treated on an outpatient basis. The most promising operative way to achieve this result is the d...
Detailed Description
Summary description of the investigational device: The RITA "Remote Intelligence for Therapeutic Adherence" application was designed, on the doctor's side, as a support for the management of the onco...
Eligibility Criteria
Inclusion
- Patients who understand and voluntarily sign an informed consent form (ICF) prior to any study related procedures being conducted;
- Patients who are ≥ 18 years old;
- Patients who are diagnosed with a onco-hematologic disease, namely: Symptomatic Multiple Myeloma, Solitary Plasmocytoma, Amyloidosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Hodgkin Lymphoma, B cells non-Hodgkin Lymphoma, T cells non-Hodgkin Lymphoma, Acute myeloid Leukemia, Myelodysplasia, Chronic Myeloproliferative Disorder;
- Patients who receive a standard of care therapy for their disease, independently from the route of administration;
- Patients in their first or subsequent line of therapy;
- Patients at the beginning of the treatment, or during therapy;
- Life expectancy \> 6 months.
Exclusion
- Patients treated with radiotherapy only;
- Presence of clinical conditions that will impair the adherence to the treatment (ie, concomitant tumor on treatment, severe neurologic disease, drug or alcohol abuse etc.);
- Patient unable to use a smartphone and/or a computer (ie blindness, inability to use a smartphone or a computer etc.);
- Major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol;
- Patient enrolled in another clinical trial.
Key Trial Info
Start Date :
June 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 16 2023
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT05260203
Start Date
June 4 2022
End Date
January 16 2023
Last Update
November 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST Santi Paolo e Carlo - SSD Ematologia - Neoplasie Ematologiche P.O. San Carlo
Milan, Milano, Italy, 20153